Tesamorelin Research Guide

Tesamorelin is a stabilized 44-amino-acid analog of human growth-hormone-releasing hormone (hGHRH 1–44). A trans-3-hexenoic acid moiety on the N-terminus extends the peptide's plasma half-life relative to native GHRH, which is otherwise rapidly degraded by dipeptidyl peptidase IV (DPP-4).

Mechanism

Tesamorelin binds the GHRH receptor on anterior-pituitary somatotrophs and stimulates endogenous pulsatile release of growth hormone (GH). The downstream consequence is an increase in hepatic IGF-1 synthesis. Because tesamorelin works upstream of the pituitary, GH release retains its physiological pulsatility and remains subject to somatostatin feedback.

Research context

• Most clinical research has focused on visceral adipose tissue (VAT) reduction in HIV-associated lipodystrophy, where tesamorelin is the only FDA-approved indication.
• Pre-clinical and exploratory studies have looked at IGF-1 dynamics, lipid metabolism, and cognitive endpoints.

Storage and handling

Lyophilized tesamorelin is stored at ≤ −20°C and protected from light. After reconstitution, refrigerated storage is typical and freeze-thaw cycles are avoided.

Quality control at Innate Research

Every vial of Tesamorelin ships with a COA documenting batch identity and purity. See how to read a COA.

References (representative)

• Falutz J, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients. NEJM. 2007.
• Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. JAMA. 2014.